Advanced search
Publication Cover
Journal of Asthma Volume 56, 2019 - Issue 7
Submit an article Journal homepage
7,951
Views
12
CrossRef citations to date
0
Altmetric
Pharmacotherapy

Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study

Loretta JacquesRespiratory Research & Development, GSK, Uxbridge, Middlesex, UK; Correspondence[email protected]
View further author information
, PhD,
Nawar Diar BakerlySalford Royal NHS Foundation Trust, Salford, UK; ;Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK; View further author information
, MD, FRCP,
John P. NewSalford Royal NHS Foundation Trust, Salford, UK; ;NorthWest EHealth, Salford, UK; View further author information
, MBBS, FRCP,
Henrik SvedsaterValue Evidence & Outcomes, GSK, Brentford, Middlesex, UK; View further author information
, PhD,
James Lay-FlurrieClinical Statistics, GSK, Uxbridge, Middlesex, UK; View further author information
, MSc &
David A. LeatherGlobal Respiratory Franchise, GSK, Brentford, Middlesex, UKView further author information
, MBChB
Pages 748-757 | Received 27 Feb 2018, Accepted 14 Jun 2018, Published online: 16 Oct 2018

References

  • Woodcock A, Vestbo J, Bakerly ND, New J, Gibson JM, McCorkindale S, Jones R, et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet 2017;390:2247–2255.
  • Global Asthma Network. Global Asthma Report (2014). Available from: http://www.globalasthmareport.org/resources/Global_Asthma_Report_2014.pdf [last accessed 15 February 2018].
  • Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention 2017. Available from: http://ginasthma.org/ [last accessed 15 Feb 2018].
  • British Thoracic Society (BTW). British Guideline on the Management of Asthma. A National Clinical Guideline 2016. Available from: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/ [last accessed 15 Feb 2018].
  • Woodcock A, Bleecker ER, Lötvall J, O'Byrne PM, Bateman ED, Medley H, Ellsworth A, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest 2013;144:1222–1229.
  • Herland K, Akselsen JP, Skjønsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med 2005;99:11–19.
  • Woodcock A, Bakerly ND, New J, Gibson JM, Wu W, Vestbo J, Leather D. The Salford Lung Study protocol: a pragmatic randomised phase III real-world effectiveness trial in asthma. BMC Pulm Med 2015;15:160.
  • Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004;113:59–65.
  • Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol 2009;124:719–723. e1
  • Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81–87.
  • Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353–365.
  • Andréasson E, Svensson K, Berggren F. The validity of the work productivity and activity impairment questionnaire for patients with asthma (WPAI-asthma): results from a web-based study. Value Health 2003;6:780.
  • O'Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, Toler WT, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J 2014;43:773–782.
  • Grant AC, Walker R, Hamilton M, Garrill K. The ELLIPTA® Dry Powder Inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. J Aerosol Med Pulm Drug Deliv 2015;28:474–485.
  • van der Palen J, Thomas M, Chrystyn H, Sharma RK, van der Valk PD, Goosens M, Wilkinson T, et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med 2016;26:16079.
  • Svedsater H, Roberts J, Patel C, Macey J, Hilton E, Bradshaw L. Life impact and treatment preferences of individuals with asthma and chronic obstructive pulmonary disease: results from qualitative interviews and focus groups. Adv Ther 2017;34:1466–1481.
  • Malik M, Khan A, Hussain A, Javaid AO. Health related quality of life in asthma: a systematic review. Arch Palliat Care 2017;2:1012.
  • Kwon SH, Lee SH, Yang MS, Lee SM, Kim SG, Kim DI, Sohn SW, et al. Correlation between the Korean version of asthma control test and health-related quality of life in adult asthmatics. J Korean Med Sci 2008;23:621–627.
  • Antonova E, Trzaskoma B, Omachi TA, Schatz M. Poor asthma control is associated with overall daily activity impairment: 3-year data from the EXCELS study of omalizaumab. J Allergy Clin Immunol Pract 2016;137:Suppl, Page AB14.
  • Svedsater H, Jones R, Bosanquet N, Jacques L, Lay-Flurrie J, Leather DA, Vestbo J, et al. Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the asthma Salford Lung Study. Respir Med 2018;141:198–206.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.